Fig. 3.
Recurrence-free survival according to EGFR amplification. Disease-free survival is significantly low in patients with EGFR amplification in primary tumor and no EGFR amplification in metastatic tumor (p=0.0454).
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.